1 Protein synthesis inhibitors (e.g. cycloheximide) prevent cells from entering mitosis, 2 suggesting that cell cycle progression requires protein synthesis until right before mitotic 3 entry. However, cycloheximide is also known to activate p38 MAPK, which can delay 4 mitotic entry through a G2/M checkpoint. Here we asked whether checkpoint activation 5 or a requirement for protein synthesis is responsible for the cycloheximide effect. We 6 found that p38 inhibitors prevent cycloheximide-treated cells from arresting in G2 phase, 7
Introduction
Early studies on human cells in tissue culture as well as cells in the intestinal crypt of rats 21 demonstrated that protein synthesis inhibitors like cycloheximide and puromycin prevent 22 cells from entering mitosis, unless the cells were already in late G2 phase at the time of 23 treatment (1, 2) . The discovery of mitotic cyclins, activators of the cyclin-dependent 24 kinases (Cdk), that accumulate prior to mitosis, provided a plausible explanation for these 25 observations (3-5). Indeed, supplementing a cycloheximide-arrested Xenopus egg 26 extract with exogenous cyclin B is sufficient to promote mitotic progression (6), as is 27 supplementing an RNase-treated extract with cyclin B mRNA (7), and blocking the 28 synthesis of cyclin B1 and B2 prevents mitotic entry (8). This argues that the synthesis of 29 this particular protein is of singular importance for M-phase initiation. 30
In human cells, mitotic cyclins, mainly cyclins A2, B1, and B2, start to accumulate around 31 the time of the G1/S transition as a result of the activation of cyclin transcription by E2F-32 family transcription factors (9) and stabilization of the cyclin proteins via APC/C Cdh1 33 inactivation (10). At the end of S phase, the ATR-mediated DNA replication checkpoint is 34 turned off, and a FOXM1-mediated transcriptional circuit is activated (11) . At about the 35 same time, the pace of cyclin B1 accumulation (12-16), as well as the accumulation of 36 other pro-mitotic regulators, including Plk1, Bora, and Aurora A, increases (12, 17, 18) . 37
These changes in transcription and protein abundances are thought to culminate in the 38 activation of mitotic kinases, especially Cdk1, and the inactivation of the counteracting 39 phosphatases PP1 and PP2A-B55 (19, 20) . Cdk1 activity -judged by substrate 40 phosphorylation -rises throughout G2 phase (12, 21) and sharply increases towards the 41 until cyclin B1 has reached a threshold concentration, beyond which the system switches 48 from low to high Cdk1 activity, and high to low Wee1/Myt1 activity ( Figure 1 to an abrupt decrease of PP2A-B55 activity (30-34). 51
The cyclin B1 threshold concentration is determined by the amounts of Cdc25 and 52 Wee1/Myt1 activity present (35). In somatic cells, several signaling pathways impinge 53 upon Cdc25 and/or Wee1 to delay the G2-to-M transition in the face of stresses (36). 54
These include the ATM/ATR kinases, which activate Chk1 and Chk2, which in turn can 55 inactivate Cdc25 and activate Wee1 by phosphorylating 14-3-3 binding sites in the two 56 Cdk1 regulators. These pathways play a role in delaying mitosis in the presence of DNA 57 damage, and may also help prevent premature mitosis in cells undergoing normal DNA 58 replication (36) (37) (38) . In addition, a protein kinase cascade that includes the MKK3 and 59 MKK6 MAP kinase kinases, p38 MAPK, and the downstream kinase MAPKAP kinase 2 60 (MK2), has been implicated in the negative regulation of Cdc25, by phosphorylating the 61 same 14-3-3 binding site (39) . Interestingly, p38 activation has been observed in 62 response to protein synthesis stresses, including cycloheximide (40); indeed 63 cycloheximide is often used as a positive control for maximal activation of p38. These 64 findings raise the question of whether the cycloheximide-dependent G2 delay is indeed 65 caused by blocking the synthesis of proteins required for mitotic entry, or rather activation 66 of the p38-dependent G2/M checkpoint. 67
Here we used live-cell markers of cell cycle progression combined with small molecule 68 inhibitors to dissect the contribution of protein synthesis to G2 and mitotic progression. 69
We show that inhibition of Wee1/Myt1 shortens the duration of G2 phase in a dose-70 dependent manner, and allows cells to progress into mitosis in the presence of 71 cycloheximide. Moreover, p38 inhibition overcomes a cycloheximide-induced G2 arrest, 72
arguing that p38-mediated checkpoint activation causes the arrest and not insufficient 73 protein synthesis. However, although G2 protein synthesis was not required for mitotic 74 entry, it was required for normal mitotic progression. These findings suggest that the burst 75 of cyclin synthesis that normally occurs during G2 phase serves as a "just-in-time" 76 preparation for mitotic progression, but does not trigger mitotic entry. 77
Results

78
We chose MCF10A cells, a spontaneously immortalized human mammary epithelial cell 79 line, for these studies, because they are euploid, non-tumorigenic, and have been studied 80 extensively (41, 42). To determine when S phase ends and G2 phase begins, we stably 81 expressed an eYFP-PCNA fusion protein, a live-cell marker of DNA replication (43, 44). 82 eYFP-PCNA forms bright foci within the nucleus during S phase, which become brighter 83 and less numerous as S phase progresses (Figure 2A,B ). We verified that eYFP-PCNA 84 foci co-localized with BrdU and EdU-staining sites of active DNA, as previously reported 85 6 (44). At the end of S phase, eYFP-PCNA foci dissolve and fluorescence becomes diffuse, 86 marking the S/G2 transition ( Figure 2B ). Upon nuclear envelope breakdown (NEB), 87 nuclear eYFP-PCNA disperses throughout the cell; this can be taken as a marker for the 88 G2/M transition (or, more precisely, of the prophase/prometaphase transition; Figure 2A ). 89
Thus eYFP-PCNA proved to be well suited to measure G2 duration, from the time of G2 90 onset (the disappearance of foci) to the time of G2 termination (taken as the time when 91 eYFP-PCNA exited the nucleus due to NEB). Typical mean G2 durations were about 4 h 92 with a variance of 25%, within the range of previously reported durations for G2 phase in 93 a variety of cell lines (12, 43, (45) (46) (47) (48) . 94 95
Live-cell imaging confirms that cycloheximide blocks entry into mitosis. 96
Early studies on fixed cells showed that the protein synthesis inhibitors puromycin and 97 cycloheximide cause cells to arrest in G2 phase (1, 2) . We confirmed this finding by live-98 cell microscopy using the PCNA probe to demarcate G2 phase. We followed 99 asynchronously growing cells in cell culture for 4-6 h, then added cycloheximide (10 100 µg/ml) and continued to follow the cells for another 6-10 h ( Figure 3A ). This allowed us to 101 identify cells which had exited S phase during the initial imaging period, determine 102 accurately how much time these cells had spent in G2 phase prior to drug addition, and 103 finally determine the fate of these cells in response to the drug treatment. Because many 104 of our subsequent experiments required the addition of DMSO-solubilized drugs to a final 105 DMSO concentration of 0.1%, we performed all experiments in the presence of this 106 concentration of DMSO. 107 Cells treated with DMSO alone progressed into mitosis (130 out of 130 cells), but 108 cycloheximide addition arrested the large majority of cells (153 cells out of 165) in G2 109 phase ( Figures 3B-D) . Cycloheximide-treated cells were more likely to progress into 110 mitosis if the drug was added late in G2 phase. Of the 12 cycloheximide-treated cells that 111 did enter mitosis, 10 had spent more than 3 h in G2 phase (>75% of the duration of a 112 normal G2 phase) at the time of cycloheximide addition ( Figure 3C ,D). Based on logistic 113 regression analysis, the probability that a cycloheximide-treated cell will enter mitosis if 114 the cycloheximide is added 2 h after the start of G2 phase is 1% (with a 95% confidence 115 interval (CI) of 0 to 7%); if added 3 h after the start of G2 phase, it rises to 4% (95% CI 1 116 to 11%); and if it is added 4 h after the start of G2 phase, the duration of a typical normal 117 G2 phase, the probability is 19 (95% CI 6 to 45%) ( Figure 3E ). The fraction of mitotic cells 118 in the cell population (mitotic index) remained approximately constant throughout the 119 experiment for the DMSO-treated population, but decreased to near-zero within 60 min 120 after cycloheximide treatment ( Figure 3F ). Together, these findings confirm that 121 cycloheximide-treated G2 cells do arrest, as previously noted (1, 2) , and imply that cells 122 remain sensitive to cycloheximide treatment until late in G2 phase. However, other studies have suggested that some Cdk1 activation can be detected early 131 in G2 phase (12), which could mean that Wee1/Myt1 is switched off earlier. These 132 possibilities can be distinguished by determining how much the duration of G2 phase can 133 be shortened by Wee1/Myt1 inhibition. In the former case, the minimal duration of G2 134 phase would be near zero; in the latter case it would be longer, with the minimal duration 135 of G2 phase corresponding to how long the interval normally is between the inactivation 136 of Wee1/Myt1 and the onset of M phase. 137
To inhibit Wee1/Myt1 activity we used the small molecule inhibitor PD0166285 (50). 138
Treating an asynchronously growing cell culture with different concentrations of 139 PD0166285 reduced the Wee1-mediated phosphorylation of Cdk1 at Tyr 15 in a dose-140 dependent manner ( Figure 4A ). 141
We next investigated the impact of Wee1/Myt1 inhibition on the duration of G2 phase by 142 live-cell imaging. Cells were treated with different concentrations of PD0166285, and 28-143 60 cells that entered and completed G2 phase over 6 h of imaging were tracked and their 144 G2 durations were determined ( Figure 4B ). PD0166285 shortened G2 phase in a graded 145 fashion. The highest concentration of PD0166285 (1 µM) resulted in a G2 duration of 38 146 ± 17 min compared to 255 ± 31 min in the DMSO-treated control (mean ± S.D., Figure  147 4B). This suggests that the Wee1/Myt1 switch is normally thrown very late in G2 phase. 148
This also suggests that there is sufficient cyclin (and any other proteins essential for M 149 phase entry) present even early in G2 phase to allow rapid mitotic entry, provided that 150 Wee1/Myt1 activity is low. Moreover, the basal level of Wee1/Myt1 activity determines the 151 length of G2 phase. These results are consistent with and extend the findings of previous 152 studies on the effects of Wee1/Myt1 inhibition (45, 50, 51) . 153
Considering the central role of Wee1/Myt1 in controlling G2/M, we asked whether 154 Wee1/Myt1 inhibition was able to overcome the cycloheximide-induced G2 arrest. We 155 used the same experimental set up as described in Figure 3A , but after the initial imaging 156 period added DMSO, cycloheximide, 1 µM PD0166285, or cycloheximide plus 1 µM 157 PD0166285 to the cells. Again (cf. Figure 3D Previous studies of Wee1 inhibitors have shown that they can drive chemotherapy-treated 184 and p53-mutant cell lines into mitosis without completing DNA replication (52). To further 185 explore the connection between protein synthesis and M-phase entry, we analyzed the 186 cell cycle progression of cells treated with cycloheximide, PD0166825, or PD0166285 187 plus cycloheximide while still in S phase. After being treated with DMSO in S phase, 100% 188 of cells (85/85) entered G2 phase and 84% (71/85) of these cells progressed into mitosis 189 during the 10 h imaging period ( Figure 5A ). In contrast, only 33% of cells (32/98) treated 190 with cycloheximide during S phase progressed into G2 phase, whereas all other cells 191 continued to display PCNA foci (albeit dimmer foci than those seen in control cells), 192 suggesting that S phase was never completed ( Figure 5A The data presented so far are consistent with the hypothesis that in G2 phase cyclin 227 synthesis triggers mitotic entry: cycloheximide blocks mitotic entry, and the effects of 228 PD0166285 suggest that some pro-mitotic activity, possibly cyclin, gradually accumulates 229 throughout G2 phase. However, it also remains possible that the ability of cycloheximide 230 to block mitotic entry is due to its activation of p38 MAPK and MK2, rather than to any 231 effect on cyclin accumulation (36, 40). 232
To address this issue directly, we treated cells with cycloheximide plus one of two p38 233 MAPK inhibitors (SB202190 and SB203580) that act as high affinity inhibitors of p38a 234 and p38b (MAPK14 and MAPK11) and as lower affinity inhibitors of other protein kinases 235 (53). We verified that, as previously reported, cycloheximide stimulated the 236 phosphorylation of p38 and its downstream target Hsp27, and that the inhibitors 237 Consistent with this notion, we had already observed that cells treated with the 277 Wee1/Myt1 inhibitor during S phase could enter mitosis (with little or no G2 phase) but 278 then exhibited pronounced mitotic errors ( Figure 5 ). In addition, a few cells treated with 279 cycloheximide plus PD0166285 during G2 phase exhibited very long mitoses ( Figure 4D) , 280 as did some cells treated with cycloheximide plus either of the p38 inhibitors ( Figure 6C) . 281 Accordingly, we examined the duration of mitosis in cells treated in G2 phase with 282 cycloheximide plus either the Wee1/Myt1 inhibitor or one of the p38 inhibitors. A 283 substantial fraction of the cells treated with PD0166285 with or without cycloheximide 284 exhibited a protracted mitosis (47% for PD-treated cells and 58% for cells treated with PD 285 plus cycloheximide, Figure 7A ), taken here as mitosis longer than two standard deviations 286 above the average duration of mitosis in DMSO-treated cells. Thus, PD-or PD-plus 287 cycloheximide treated cells that successfully entered mitosis were, nevertheless, delayed 288 in their progression through M phase. These results confirm previous findings that 289 Wee1/Myt1 inhibition extends the mitotic duration (45). The duration of mitosis was a 290 dose-dependent function of the PD0166285 concentration ( Figure 7B ; cf. Figure 4B) . 291
Moreover, the greater the shortening of G2 phase, the greater the delay in M phase 292 ( Figure 7-figure supplement 1) . 293
For the p38 inhibitors SB202190 and SB203580, the drugs had some effect on the 294 duration of mitosis even in the absence of cycloheximide; 17% (SB202190) and 4.5% 295 (SB203580) of the drug-treated cells exhibited a protracted mitosis, versus 0% for the 296 DMSO-treated controls ( Figure 7C ). This suggests that p38 function may contribute to M-297 phase progression in at least a subset of cells. A greater proportion of cells treated with 298 either of the inhibitors plus cycloheximide exhibited a protracted mitosis (50% and 34% 299 respectively), suggesting that the protein synthesis that normally occurs during G2 phase 300 helps cells to progress through M phase in a timely fashion. The cycloheximide effect appears not to be due to the inhibition of protein synthesis per 313 se, but rather to the activation of p38 MAPKs. Accordingly, the p38 inhibitors SB202190 314 and SB203580 largely restored mitotic entry in cycloheximide-treated cells ( Figure 6 and 315 (Figure 4 ). Taken together, these results suggest that G2 319 phase cyclin synthesis, and G2 phase protein synthesis in general, is not strictly required 320 for timely progression into M phase. 321
These findings also suggest that the accelerating accumulation of cyclin B1 that normally 322 begins at about the onset of G2 phase is not the trigger for mitosis, or at least not the only 323 trigger, since normal G2 durations can be seen in the absence of such protein synthesis. 324
This conclusion fits well with loss of function studies that show that cyclin A2 synthesis 325 but not cyclin B1 synthesis is required for mitotic entry (57-59). Likewise, the current 326 findings fit well with the observation that cyclin B1 overexpression has little or no effect 327 on cell cycle dynamics (60). 328
What then is the trigger for mitosis? One possibility is that the cessation of some low but 329 non-zero levels of ATR-or ATM-mediated checkpoint signaling (11, 57) at the S/G2 330 boundary might set into motion a signal transduction process that leads to inactivation or 331 degradation of Wee1/Myt1 (61-63) and activation of Cdc25. Consistent with this 332 hypothesis, we observed that the duration of G2 phase is a sensitive function of the basal 333 level of Wee1/Myt1 activity ( Figure 4B ). Another possibility is that the translocation of 334 cyclin A2 from the nucleus to the cytoplasm, an event that occurs during late S phase, 335 may initiate the events that lead to mitotic entry (64, 65). A third possibility is that the 336 Bora-Aurora A-Plk1 pathway is the critical trigger (18, 66). How exactly cells integrate the 337 different signaling pathways in order to decide whether or not to enter mitosis remains an 338 important, open question in somatic cell cycle regulation. 339
Cycloheximide-treated cells rescued by p38 MAPK inhibition, and cells entering mitosis 340
precociously due to Wee1/Myt1 inhibition, did take longer to progress through and exit 341 mitosis (Figure 7) . In both cases, these cells would be expected to enter mitosis with lower 342 cyclin B1 levels than normal. The lower cyclin B1 levels could result in all or some mitotic 343 substrates being phosphorylated more slowly, resulting in the observed mitotic delays. 344 G2 phase protein synthesis, or cyclin B1 synthesis more specifically, appears to represent 345 "just-in-time" preparation for the next phase of the cell cycle. This concept, borrowed from 346 supply chain management, has been proposed to apply to protein synthesis and complex 347 assembly in the bacterial cell cycle (67). Even though the proteins involved in the bacterial 348 cell cycle bear little resemblance to those that regulate the eukaryotic cell cycle, perhaps 349 this concept applies to both regulatory systems. 350 penicillin, and 1% streptomycin. All cells were maintained at 37°C and 5% CO2 and 367 discarded after passage 25. 368
Materials and Methods
Stable cell lines 369
To obtain MCF10A cells stably expressing eYFP-PCNA, we sub-cloned eYFP-PCNA 370 from the eYFP-PCNA construct (43) into the pTRIP-EF1α lentiviral transfer vector (68), 371 kindly provided by Ed Grow at Stanford University, by using the XbaI and BamHI 372 restriction sites. To make lentivirus, we incubated 1 ml Opti-MEM and 36 μl FuGENE6 for 373 5 min at room temperature, then added 10 μg pTRIP-EF1α-eYFP-PCNA, and 6.6 μg 374 pCMVΔR8.74, 3.3 μg pMD.G-VSVG, and 3.3 μg pRev (all kindly provided by Ed Grow), 375 and incubated for 30 min. We used this to transfect HEK 293T cells in Opti-MEM for 6 h 376 at 37°C and 5% CO2 and then exchanged with fresh Opti-MEM. We harvested medium 377 containing virus 48 h, 72 h, and 96 h later, filtered out cell debris with a sterile 0.45-μm 378 filter (Millipore), concentrated by centrifuging for 20 min at 3600 rpm in Amicon-Ultra 15 379
Filter Units with a 100,000 kDa MW cutoff (Millipore), and froze down at -80°C. To 380 transduce MCF10A cells, we added concentrated virus and 5 μg/ml polybrene (Sigma-381 Aldrich) to MCF10A cells in growth media, incubated for 24 h, and replaced with growth 382 media. After culturing cells for 5 more days, we sorted for eYFP-positive cells by 383 fluorescence-activated cell sorting. To obtain MCF10A cells stably expressing eYFP-384 PCNA and histone H2B-mCherry or histone H2B-mTurquoise we made lentivirus as 385 above with histone H2B-mCherry or histone H2B-mTurquoise sub-cloned into the CSII-386 EF lentiviral transfer vector (69). We used it to transduce MCF10A cells stably expressing 387 eYFP-PCNA and then sorted for cells positive for both fluorescent proteins using 388 fluorescence-activated cell sorting. The hTERT RPE-1 cells stably expressing eYFP-389 PCNA and histone H2B-mTurquoise cells were produced in the same manner. 390
To obtain HeLa cells stably expressing eYFP-PCNA, we linearized the eYFP-PCNA 391 construct (43) by incubating with FspI (New England Biolabs) and purifying with ethanol 392 precipitation. We co-transfected linearized eYFP-PCNA and linearized hygromycin 393 marker (Clontech) with FuGENE6 (Promega) at a ratio of 1 μg eYFP-PCNA to 0.1 μg 394 hygromycin marker to 6 μl FuGENE6 according to the manufacturer's instructions except 395 that we washed cells with Opti-MEM (Invitrogen), transfected cells in Opti-MEM, and 396 incubated in Opti-MEM for 5 h at 37°C and 5% CO2 before replacing with growth medium. 397
We split cells 48 h later and after 25 more h added 400 μg/ml hygromycin B (Invitrogen). 398
We picked colonies 11 days later using cloning rings and expanded a clone that had 399 correct PCNA localization in the nucleus and could form PCNA foci. 400 For some analyses we used a graphical user interface written in LabView (National 429 Instruments) that recorded the frame number and cell coordinates by responding to a 430 mouse click and exported results to Excel (Microsoft). To allow features like PCNA foci to 431 be easily perceived, images were typically min-max adjusted, and we sometimes allowed 432 the H2B-mCherry image to be saturated in the mitotic stages in order to allow the low 433 intensity H2B-mCherry signal in interphase to be perceivable. A custom-written Matlab 434 script provided by Tobias Meyer's laboratory was used to count the total number of cells 435 in every time frame in order to calculate mitotic indices. 436
Chemical inhibitors 401
Immunoblotting and antibodies 437 2 ml of MCF10A cell suspension at a cell concentration of 1.5 x 10 5 cells/ml was seeded 438 into a 6-well plate (Falcon, #353046) and grown for 48 h at 37°C. The medium was 439 exchanged and the cells were grown for another 6 h. An equal volume of medium 440 containing the prediluted inhibitors was then added to the cells, and the cells were 441 incubated for 30 min (for PD0166285) or 6 h (for cycloheximide and cycloheximide plus 442 either SB202190 or SB203580). The medium was then removed, cells were washed twice 443 with cold PBS and lysed with lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-444 40, 1 mM EDTA, 1x Phosstop #4906845001, 1x cOmplete #11873580001). Samples 445 were boiled in SDS PAGE sample buffer and analyzed by SDS PAGE and 446 immunoblotting. The following antibodies were used: rabbit a-Cdk1 phospho-Tyr15 (Cell 447
Signaling Technology, #9111L), mouse a-Cdk1 (Santa Cruz Biotechnology #SC-54), 448 mouse a-tubulin (Santa Cruz Biotechnology #SC-32293), rabbit a-HSP27 phospho-449 Ser82 (Cell Signaling Technology, #2401), mouse a-HSP27 (Cell Signaling Technology, 450 #2402), rabbit a-p38 MAPK (Cell Signaling Technology, #9212) and rabbit a-p38 MAPK 451 phospho-Thr180/Tyr182 (Cell Signaling Technology, #9211). 452
Statistical analysis 453
Logistic regression analysis is a method for estimating how the probability of a binary 454 outcome-in our case, whether a cell does or does not ultimately progress into mitosis-455 varies as a function of time and treatment conditions. The underlying assumption is that 456 the odds of progressing into mitosis scale multiplicatively with time, which means that the 457 time course data should be approximated by a logistic function, with parameters for the 458 steepness and time of the transition from low to high probability. We binarized cell 459 outcomes (i.e., the cell either did or did not progress into mitosis within the average G2 460 phase duration plus two standard deviations of the DMSO-treated control ), plotted the 461 fraction of cells that attained the outcome as a function of the time of drug addition, and 462 fitted the data to a logistic function using the LogitModelFit command in Mathematica 10. 463
The 95% confidence bands were calculated using code deposited in the Mathematica 464 at the time of drug addition for cells treated with DMSO, or cycloheximide plus either SB202190 or 203580. Blue, solid line depicts the mean G2 duration for the DMSO control and the light blue, shaded area marks the area that falls within two standard deviations of the mean. Circles depict cells that entered mitosis during the experiment, triangles depict cells that were still in G2 at the end of the experiment. In order to better differentiate data points in the x-dimension minimal random noise was added to each data point. Mitotic timing (measured as the time from nuclear envelope breakdown to anaphase onset) for cells that were treated with cycloheximide for 2 h before the addition of 1 µM PD0166285 as a function of how much time the cell had spent in G2 phase at the time of cycloheximide addition. In order to better differentiate data points in the x-dimension minimal random noise was added to each data point. Note that cells that had spent less time in G2 phase at cycloheximide addition, required more time to progress into anaphase.
